Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.49 |
| ▸ | BCL9 | O00512 | 9/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 9/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31111503 | 0.94 | PDE4B (0.57) | PDE4BUSP30NR1H2HPGDSGPR119 | |
| SCHEMBL528060 | 0.94 | PDE4B (0.57) | PDE4BUSP30NR1H2HPGDSGPR119 | |
| SCHEMBL4189282 | 0.89 | NR1H2 (0.48) | PDE4BUSP30NR1H2GPR119 | |
| SCHEMBL4031537 | 0.87 | SIGMAR1 (0.54) | PDE4BUSP30BCL9CTNNB1PRMT5 | |
| SCHEMBL30376009 | 0.86 | GPR119 (0.54) | PDE4BNR1H2GPR119 | |
| SCHEMBL835855 | 0.86 | GPR119 (0.54) | PDE4BNR1H2GPR119 | |
| SCHEMBL14855709 | 0.86 | DRD2 (0.53) | PDE4BUSP30BCL9CTNNB1HPGDS | |
| SCHEMBL1988650 | 0.85 | PDE4B (0.52) | PDE4BUSP30NR1H2HPGDSPRMT5 | |
| SCHEMBL1421908 | 0.85 | PDE4B (0.52) | PDE4BUSP30NR1H2HPGDSPRMT5 | |
| SCHEMBL1422394 | 0.85 | PDE4B (0.52) | PDE4BUSP30NR1H2HPGDSPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-07-25 | — | — | US | disclosed |
| CN-112300172-B | Bruton tyrosine kinase inhibitors | 比奥根MA公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN MA INC. | 2023-02-16 | — | — | US | disclosed |
| CN-112300172-A | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | VIRACTA THERAPEUTICS, INC. | 2020-12-24 | — | — | US | disclosed |
| CN-107011330-B | Bruton's tyrosine kinase inhibitors | 比奥根MA公司 | 2020-07-03 | — | — | CN | disclosed |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2011-06-30 | — | — | US | disclosed |
| EP-2311802-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2311803-A1 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | Abbott GmbH & Co. KG (DE) | 2011-04-20 | — | — | EP | disclosed |
| EP-1814849-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011029046-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011029046-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246988-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | PDE4B 1362/4885USP30 1989/4885BCL9 42/4885 |
| US-20230046457-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | PDE4B 1362/4885USP30 1989/4885BCL9 42/4885 |
| US-20110160176-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | DRD3, CHRNA3, CHRM3 | PDE4B 1819/4885USP30 4395/4885BCL9 2693/4885 |
| US-20200399283-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | BTK, ABL1, SYK | PDE4B 1362/4885USP30 1989/4885BCL9 42/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | PDE4B 1773/4885USP30 4329/4885BCL9 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.